Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results

被引:46
作者
Xu, Chuanjun [1 ]
Li, Lei [2 ]
Xu, Wei [2 ]
Du, Chao [1 ]
Yang, Lixin [3 ]
Tong, Jinlong [4 ]
Yi, Yongxiang [5 ]
机构
[1] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Radiol, Nanjing, Jiangsu, Peoples R China
[2] Qingdao Univ, Affiliated Cent Hosp, Dept Intervent Radiol, Qingdao, Shandong, Peoples R China
[3] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Ultrasound, Nanjing, Jiangsu, Peoples R China
[4] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Oncol, Nanjing, Jiangsu, Peoples R China
[5] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Hepatobiliary Surg, 1 Zhongfu Rd, Nanjing 21003, Jiangsu, Peoples R China
关键词
Intrahepatic cholangiocarcinoma; microwave ablation; surgical resection; percutaneous; ultrasound-guided; HEPATOCELLULAR-CARCINOMA; THERMAL ABLATION; SURVIVAL;
D O I
10.1080/02656736.2019.1571247
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aims of this study were to compare the clinical outcomes between ultrasound-guided percutaneous microwave ablation (US-PMWA) and surgical resection (SR) in patients with recurrent intrahepatic cholangiocarcinoma (ICC) and to identify the prognostic factors associated with the two treatment methods. Methods: This retrospective study was institutional review board approved. A total of 121 patients (102 men and 19 women) with 136 ICCs after hepatectomy from April 2011 to January 2017 were reviewed. Fifty-six patients underwent US-PMWA and 65 patients underwent SR. Survival, recurrence and liver function were compared between the two groups. Effect of changes in key parameters [i.e., overall survival (OS) and recurrence-free survival (RFS)] was statistically analyzed with the log-rank test. Univariate and multivariate analysis were performed on clinicopathological variables to identify factors affecting long-term outcome. Results: The OS and RFS after MWA were comparable to that of SR (p = .405, and p = .589, respectively). Estimated 5-year OS rates were 23.7% after MWA and 21.8% after SR; for RFS, estimated 3-year RFS rates were 33.1% after MWA and 30.6% after SR. Major complication rates in SR group were higher than that in MWA (p < .001) (SR, 13.8% vs. MWA, 5.3%). Multivariate analysis showed tumor number (p = .012), ALBI grade (p = .007), and metastasis (p = .016), may become OS rate predictors. Conclusions: US-PMWA had comparable oncologic outcomes with SR and could be a safe and effective treatment for recurrent ICC after hepatectomy.
引用
收藏
页码:351 / 358
页数:8
相关论文
共 31 条
  • [1] Ahmed M, 2014, RADIOLOGY, V273, P241, DOI [10.1148/radiol.14132958, 10.1016/j.jvir.2014.08.027]
  • [2] Antwi SO, 2018, ANN HEPATOL, V17, P274, DOI [10.5604/01.3001.0010.8663, 10.5604/01.3001.0010.8659, 10.5604/01.3001.0012.0929]
  • [3] Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
    Burt, Alastair D.
    Alves, Venancio
    Bedossa, Pierre
    Clouston, Andrew
    Guido, Maria
    Hubscher, Stefan
    Kakar, Sanjay
    Ng, Irene
    Park, Young N.
    Reeves, Helen
    Wyatt, Judith
    Yeh, Matthew M.
    Ellis, David W.
    [J]. HISTOPATHOLOGY, 2018, 73 (03) : 369 - 385
  • [4] Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome
    Butros, Selim R.
    Shenoy-Bhangle, Anuradha
    Mueller, Peter R.
    Arellano, Ronald S.
    [J]. CLINICAL IMAGING, 2014, 38 (04) : 490 - 494
  • [5] Survival Analysis of Intrahepatic Cholangiocarcinoma After Resection
    Cho, Seong Yeon
    Park, Sang-Jae
    Kim, Seong Hoon
    Han, Sung-Sik
    Kim, Young-Kyu
    Lee, Kwang-Woong
    Lee, Soon-Ae
    Hong, Eun Kyung
    Lee, Woo Jin
    Woo, Sang Myung
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (07) : 1823 - 1830
  • [6] Use of microwave ablation in the treatment of patients with multiple primary malignant tumors
    Han, Yue
    Shao, Na
    Xi, Xiaoming
    Hao, Xuezhi
    [J]. THORACIC CANCER, 2017, 8 (04) : 365 - 371
  • [7] ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function
    Hiraoka, Atsushi
    Michitaka, Kojiro
    Kumada, Takashi
    Kudo, Masashi
    [J]. LIVER CANCER, 2017, 6 (04) : 377 - 379
  • [8] Ho Connie H M, 2018, Oncotarget, V9, P28818, DOI 10.18632/oncotarget.25522
  • [9] Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation
    Ho, Shu-Yein
    Liu, Po-Hong
    Hsu, Chia-Yang
    Chiou, Yi-You
    Su, Chien-Wei
    Lee, Yun-Hsuan
    Huang, Yi-Hsiang
    Lee, Fa-Yauh
    Hou, Ming-Chih
    Huo, Teh-Ia
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [10] Hou Y L, 2018, Zhonghua Yi Xue Za Zhi, V98, P127, DOI 10.3760/cma.j.issn.0376-2491.2018.02.011